Hanmi's Amodipine success to be resumed with Slimmer?
Published: 2007-07-10 07:00:00
Updated: 2007-07-10 07:00:00
Hanmi has developed a modified new anti-obesity drug based on sibutramine (Reductil) expecting a similar market success perspective with Amodipine, another modified amlodipine preparation being remarkably succeeded in the market.
Amodipine, a modified amlodpine (Novarsc) made a great success w...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
